Mitochondria: A therapeutic target for Parkinson’s disease?

International Journal of Molecular Sciences

Volumn 16, Issue 9, 2015, Pages 20704-20730

  Luo, Yu ^a   Hoffer, Alan ^a   Hoffer, Barry ^a   Qi, Xin ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Mitochondrial dynamics; Mitochondrial dysfunction; Parkinson s disease

Indexed keywords

3 (3, 5 DIBROMO 4 HYDROXYBENZYLIDENE) 1, 3 DIHYDRO 5 IODO 2 INDOLONE; 4, 4' [(1 PHENYL 1H PYRAZOLE 3, 5 DIYL) DIETHENE 2, 1 DIYL] BIS (2 METHOXYPHENOL); ALDEHYDE DEHYDROGENASE ISOENZYME 2; ALDIOXA; ALPHA SYNUCLEIN; DJ 1 PROTEIN; DYNAMIN I; LEUCINE RICH REPEAT KINASE 2; LYCOPENE; MELATONIN; MITOCHONDRIAL PROTEIN; MITOFUSIN 1; NORPHENAZONE; PARKIN; PROTEIN P110; QUERCETIN; RAPAMYCIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; ROTENONE; THIOCTIC ACID; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL; MITOCHONDRIAL DNA; TOXIN;

DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; ENERGY YIELD; GENE DELETION; GENE MUTATION; HEREDITY; HUMAN; MITOCHONDRIAL DYNAMICS; MITOCHONDRION; MITOPHAGY; OXIDATIVE STRESS; PARKINSON DISEASE; PINK1 MUTANT (DROSOPHILA); REVIEW; ANIMAL; AUTOPHAGY; DRUG EFFECTS; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; OXIDATION REDUCTION REACTION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

ANIMALS; AUTOPHAGY; DNA, MITOCHONDRIAL; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DEGRADATION; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL PROTEINS; MOLECULAR TARGETED THERAPY; MUTATION; OXIDATION-REDUCTION; PARKINSON DISEASE; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TOXINS, BIOLOGICAL;

EID: 84940837370     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160920704     Document Type: Review

References (203)

1. Duvoisin, R.C. Overview of Parkinson’s disease. Ann. N. Y. Acad. Sci. 1992, 648, 187-193
2. Dauer, W.; Przedborski, S. Parkinson’s disease: Mechanisms and models. Neuron 2003, 39, 889-909
3. Dawson, T.M.; Dawson, V.L. Molecular pathways of neurodegeneration in Parkinson’s disease. Science 2003, 302, 819-822
4. Yao, Z.; Wood, N.W. Cell death pathways in Parkinson’s disease: Role of mitochondria. Antioxid. Redox Signal. 2009, 11, 2135-2149
5. Ellis, C.E.; Murphy, E.J.; Mitchell, D.C.; Golovko, M.Y.; Scaglia, F.; Barcelo-Coblijn, G.C.; Nussbaum, R.L. Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synuclein. Mol. Cell. Biol. 2005, 25, 10190-10201
6. Herrmann, J.M.; Longen, S.; Weckbecker, D.; Depuydt, M. Biogenesis of mitochondrial proteins. Adv. Exp. Med. Biol. 2012, 748, 41-64
7. Sas, K.; Robotka, H.; Toldi, J.; Vecsei, L. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J. Neurol. Sci. 2007, 257, 221-239
8. Daiber, A. Redox signaling (cross-talk) from and to mitochondria involves mitochondrial pores and reactive oxygen species. Biochim. Biophys. Acta 2010, 1797, 897-906
9. Bononi, A.; Missiroli, S.; Poletti, F.; Suski, J.M.; Agnoletto, C.; Bonora, M.; de Marchi, E.; Giorgi, C.; Marchi, S.; Patergnani, S.; et al. Mitochondria-associated membranes (MAMs) as hotspot Ca2+ signaling units. Adv. Exp. Med. Biol. 2012, 740, 411-437
10. Rizzuto, R.; de Stefani, D.; Raffaello, A.; Mammucari, C. Mitochondria as sensors and regulators of calcium signalling. Nat. Rev. Mol. Cell Biol. 2012, 13, 566-578
11. Cali, T.; Ottolini, D.; Brini, M. Mitochondrial Ca2+ as a key regulator of mitochondrial activities. Adv. Exp. Med. Biol. 2012, 942, 53-73
12. Osteryoung, K.W.; Nunnari, J. The division of endosymbiotic organelles. Science 2003, 302, 1698-704
13. Antico Arciuch, V.G.; Elguero, M.E.; Poderoso, J.J.; Carreras, M.C. Mitochondrial regulation of cell cycle and proliferation. Antioxid. Redox Signal. 2012, 16, 1150-1180
14. Moyes, C.D.; Hood, D.A. Origins and consequences of mitochondrial variation in vertebrate muscle. Annu. Rev. Physiol. 2003, 65, 177-201
15. Schatten, H.; Prather, R.S.; Sun, Q.Y. The significance of mitochondria for embryo development in cloned farm animals. Mitochondrion 2005, 5, 303-321
16. Giorgi, C.; Baldassari, F.; Bononi, A.; Bonora, M.; de Marchi, E.; Marchi, S.; Missiroli, S.; Patergnani, S.; Rimessi, A.; Suski, J.M.; et al. Mitochondrial Ca2+ and apoptosis. Cell Calcium 2012, 52, 36-43
17. Rasola, A.; Bernardi, P. Mitochondrial permeability transition in Ca2+-dependent apoptosis and necrosis. Cell Calcium 2011, 50, 222-233
18. Wang, C.; Youle, R.J. The role of mitochondria in apoptosis*. Annu. Rev. Genet. 2009, 43, 95-118
19. Burbach, J.P.; Smits, S.; Smidt, M.P. Transcription factors in the development of midbrain dopamine neurons. Ann. N. Y. Acad. Sci. 2003, 991, 61-68
20. Wallen, A.; Perlmann, T. Transcriptional control of dopamine neuron development. Ann. N. Y. Acad. Sci. 2003, 991, 48-60
21. Dreyer, S.D.; Zhou, G.; Baldini, A.; Winterpacht, A.; Zabel, B.; Cole, W.; Johnson, R.L.; Lee, B. Mutations in LMX1B cause abnormal skeletal patterning and renal dysplasia in nail patella syndrome. Nat. Genet. 1998, 19, 47-50
22. Smidt, M.P.; van Schaick, H.S.; Lanctot, C.; Tremblay, J.J.; Cox, J.J.; van der Kleij, A.A.; Wolterink, G.; Drouin, J.; Burbach, J.P. A homeodomain gene Ptx3 has highly restricted brain expression in mesencephalic dopaminergic neurons. Proc. Natl Acad. Sci. USA 1997, 94, 13305-13310
23. Smidt, M.P.; Asbreuk, C.H.; Cox, J.J.; Chen, H.; Johnson, R.L.; Burbach, J.P. A second independent pathway for development of mesencephalic dopaminergic neurons requires Lmx1b. Nat. Neurosci. 2000, 3, 337-341
24. Mann, V.M.; Cooper, J.M.; Daniel, S.E.; Srai, K.; Jenner, P.; Marsden, C.D.; Schapira, A.H.; Complex, I, iron, and ferritin in Parkinson’s disease substantia nigra. Ann. Neurol. 1994, 36, 876-881
25. Blandini, F.; Nappi, G.; Greenamyre, J.T. Quantitative study of mitochondrial complex I in platelets of parkinsonian patients. Mov. Disord. 1998, 13, 11-15
26. Haas, R.H.; Nasirian, F.; Nakano, K.; Ward, D.; Pay, M.; Hill, R.; Shults, C.W. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson’s disease. Ann. Neurol. 1995, 37, 714-722
27. Barroso, N.; Campos, Y.; Huertas, R.; Esteban, J.; Molina, J.A.; Alonso, A.; Gutierrez-Rivas, E.; Arenas, J. Respiratory chain enzyme activities in lymphocytes from untreated patients with Parkinson disease. Clin. Chem. 1993, 39, 667-69
28. Yoshino, H.; Nakagawa-Hattori, Y.; Kondo, T.; Mizuno, Y. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson’s disease. J. Neural Transm Parkinsons Dis. Dement. Sect. 1992, 4, 27-34
29. Dias, V.; Junn, E.; Mouradian, M.M. The role of oxidative stress in Parkinson’s disease. J. Parkinsons Dis. 2013, 3, 461-491
30. Hwang, O. Role of oxidative stress in Parkinson’s disease. Exp. Neurobiol. 2013, 22, 11-17
31. Bender, A.; Krishnan, K.J.; Morris, C.M.; Taylor, G.A.; Reeve, A.K.; Perry, R.H.; Jaros, E.; Hersheson, J.S.; Betts, J.; Klopstock, T.; et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 2006, 38, 515-517
32. Kraytsberg, Y.; Kudryavtseva, E.; McKee, A.C.; Geula, C.; Kowall, N.W.; Khrapko, K. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat. Genet. 2006, 38, 518-520
33. Langston, J.W.; Ballard, P.; Tetrud, J.W.; Irwin, I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219, 979-980
34. Betarbet, R.; Sherer, T.B.; MacKenzie, G.; Garcia-Osuna, M.; Panov, A.V.; Greenamyre, J.T. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat. Neurosci. 2000, 3, 1301-1306
35. Testa, C.M.; Sherer, T.B.; Greenamyre, J.T. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res. Mol. Brain Res. 2005, 134, 109-118
36. Smeyne, R.J.; Jackson-Lewis, V. The MPTP model of Parkinson’s disease. Brain Res. Mol. Brain Res. 2005, 134, 57-66
37. Langston, J.W.; Ballard, P.A., Jr. Parkinson’s disease in a chemist working with 1-methyl-4- phenyl-1,2,5,6-tetrahydropyridine. N. Engl. J. Med. 1983, 309, 310
38. Kopin, I.J. Toxins and Parkinson’s disease: MPTP parkinsonism in humans and animals. Adv. Neurol. 1987, 45, 137-144
39. Barbeau, A. Parkinson’s disease: Clinical features and etiopahthology. In Amsterdam Handbook of Clinical Neurology; Viken, P.J., Bruyn, G.W., Klawans, H.L., Eds.; Elsevier Science Publishers: Amsterdam, The Netherlands, 1986; pp. 87-108
40. Jenner, P.; Olanow, C.W. Understanding cell death in Parkinson’s disease. Ann. Neurol. 1998, 44 (Suppl. 1), S72-S84
41. Nunes, I.; Tovmasian, L.T.; Silva, R.M.; Burke, R.E.; Goff, S.P. Pitx3 is required for development of substantia nigra dopaminergic neurons. Proc. Natl. Acad. Sci. USA 2003, 100, 4245-4250
42. Van den Munckhof, P.; Luk, K.C.; Ste-Marie, L.; Montgomery, J.; Blanchet, P.J.; Sadikot, A.F.; Drouin, J. Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons. Development 2003, 130, 2535-2542
43. Klein, C.; Westenberger, A. Genetics of Parkinson’s disease. Cold Spring Harb. Perspect. Med. 2012, 2, a008888
44. Zetterstrom, R.H.; Solomin, L.; Jansson, L.; Hoffer, B.J.; Olson, L.; Perlmann, T. Dopamine neuron agenesis in Nurr1-deficient mice. Science 1997, 276, 248-250
45. Wallen, A.; Zetterstrom, R.H.; Solomin, L.; Arvidsson, M.; Olson, L.; Perlmann, T. Fate of mesencephalic AHD2-expressing dopamine progenitor cells in NURR1 mutant mice. Exp. Cell Res. 1999, 253, 737-46
46. Smidt, M.P.; Smits, S.M.; Burbach, J.P. Molecular mechanisms underlying midbrain dopamine neuron development and function. Eur. J. Pharmacol. 2003, 480, 75-88
47. Franco-Iborra, S.; Vila, M.; Perier, C. The Parkinson Disease Mitochondrial Hypothesis: Where Are We at? Neuroscientist 2015, doi:10.1177/1073858415574600
48. Luoma, P.; Melberg, A.; Rinne, J.O.; Kaukonen, J.A.; Nupponen, N.N.; Chalmers, R.M.; Oldfors, A.; Rautakorpi, I.; Peltonen, L.; Majamaa, K.; et al. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: Clinical and molecular genetic study. Lancet 2004, 364, 875-882
49. Henchcliffe, C.; Beal, M.F. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat. Clin. Pract. Neurol. 2008, 4, 600-609
50. Zheng, B.; Liao, Z.; Locascio, J.J.; Lesniak, K.A.; Roderick, S.S.; Watt, M.L.; Eklund, A.C.; Zhang-James, Y.; Kim, P.D.; Hauser, M.A.; et al. PGC-1α, a potential therapeutic target for early intervention in Parkinson’s disease. Sci. Transl Med. 2010, 2, 52ra73
51. Ekstrand, M.I.; Terzioglu, M.; Galter, D.; Zhu, S.; Hofstetter, C.; Lindqvist, E.; Thams, S.; Bergstrand, A.; Hansson, F.S.; Trifunovic, A.; et al. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc. Natl. Acad. Sci. USA 2007, 104, 1325-1330
52. Ekstrand, M.I.; Galter, D. The MitoPark Mouse—An animal model of Parkinson’s disease with impaired respiratory chain function in dopamine neurons. Parkinsonism Relat. Disord. 2009, 15 (Suppl. 3), S185-S188
53. Gellhaar, S.; Marcellino, D.; Abrams, M.B.; Galter, D. Chronic L-DOPA induces hyperactivity, normalization of gait and dyskinetic behavior in MitoPark mice. Genes Brain Behav. 2015, 14, 260-270
54. Ikebe, S.; Tanaka, M.; Ohno, K.; Sato, W.; Hattori, K.; Kondo, T.; Mizuno, Y.; Ozawa, T. Increase of deleted mitochondrial DNA in the striatum in Parkinson’s disease and senescence. Biochem. Biophys. Res. Commun. 1990, 170, 1044-1048
55. Lee, V.M.; Trojanowski, J.Q. Mechanisms of Parkinson’s disease linked to pathological alpha-synuclein: New targets for drug discovery. Neuron 2006, 52, 33-38
56. Peelaerts, W.; Bousset, L.; van der Perren, A.; Moskalyuk, A.; Pulizzi, R.; Giugliano, M.; van den Haute, C.; Melki, R.; Baekelandt, V. Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 2015, 522, 340-344
57. Selkoe, D.; Dettmer, U.; Luth, E.; Kim, N.; Newman, A.; Bartels, T. Defining the native state of alpha-synuclein. Neurodegener. Dis. 2014, 13, 114-117
58. Riess, O.; Jakes, R.; Kruger, R. Genetic dissection of familial Parkinson’s disease. Mol. Med. Today 1998, 4, 438-444
59. De Silva, H.R.; Khan, N.L.; Wood, N.W. The genetics of Parkinson’s disease. Curr. Opin. Genet. Dev. 2000, 10, 292-298
60. Tan, J.M.; Dawson, T.M. Parkin blushed by PINK1. Neuron 2006, 50, 527-529
61. Kubo, S.; Hattori, N.; Mizuno, Y. Recessive Parkinson’s disease. Mov. Disord. 2006, 21, 885-893
62. Giasson, B.I.; Duda, J.E.; Quinn, S.M.; Zhang, B.; Trojanowski, J.Q.; Lee, V.M. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002, 34, 521-533
63. Lee, M.K.; Stirling, W.; Xu, Y.; Xu, X.; Qui, D.; Mandir, A.S.; Dawson, T.M.; Copeland, N.G.; Jenkins, N.A.; Price, D.L. Human alpha-synuclein-harboring familial Parkinson’s disease-linked Ala-53 —> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. USA 2002, 99, 8968-8973
64. Gispert, S.; Del Turco, D.; Garrett, L.; Chen, A.; Bernard, D.J.; Hamm-Clement, J.; Korf, H.W.; Deller, T.; Braak, H.; Auburger, G.; et al. Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol. Cell. Neurosci. 2003, 24, 419-429
65. Neumann, M.; Kahle, P.J.; Giasson, B.I.; Ozmen, L.; Borroni, E.; Spooren, W.; Muller, V.; Odoy, S.; Fujiwara, H.; Hasegawa, M.; et al. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J. Clin. Investig. 2002, 110, 1429-11439
66. Rockenstein, E.; Mallory, M.; Hashimoto, M.; Song, D.; Shults, C.W.; Lang, I.; Masliah, E. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J. Neurosci. Res. 2002, 68, 568-578
67. Fleming, S.M.; Salcedo, J.; Fernagut, P.O.; Rockenstein, E.; Masliah, E.; Levine, M.S.; Chesselet, M.F. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J. Neurosci. 2004, 24, 9434-9440
68. Chen, L.; Xie, Z.; Turkson, S.; Zhuang, X. A53T human alpha-synuclein overexpression in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron degeneration. J. Neurosci. 2015, 35, 890-905
69. Li, Y.; Liu, W.; Oo, T.F.; Wang, L.; Tang, Y.; Jackson-Lewis, V.; Zhou, C.; Geghman, K.; Bogdanov, M.; Przedborski, S.; et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson’s disease. Nat. Neurosci. 2009, 12, 826-828
70. Dranka, B.P.; Gifford, A.; McAllister, D.; Zielonka, J.; Joseph, J.; O'Hara, C.L.; Stucky, C.L.; Kanthasamy, A.G.; Kalyanaraman, B. A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse model of Parkinson’s disease. Neurosci. Lett. 2014, 583, 159-164
71. Yue, M.; Hinkle, K.M.; Davies, P.; Trushina, E.; Fiesel, F.C.; Christenson, T.A.; Schroeder, A.S.; Zhang, L.; Bowles, E.; Behrouz, B.; et al. Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol. Dis. 2015, 78, 172-195
72. Goldberg, M.S.; Fleming, S.M.; Palacino, J.J.; Cepeda, C.; Lam, H.A.; Bhatnagar, A.; Meloni, E.G.; Wu, N.; Ackerson, L.C.; Klapstein, G.J.; et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 2003, 278, 43628-43635
73. Perez, F.A.; Palmiter, R.D. Parkin-deficient mice are not a robust model of parkinsonism. Proc. Natl. Acad. Sci. USA 2005, 102, 2174-2179
74. Lopert, P.; Patel, M. Brain mitochondria from DJ-1 knockout mice show increased respiration-dependent hydrogen peroxide consumption. Redox Biol. 2014, 2, 667-672
75. Akundi, R.S.; Huang, Z.; Eason, J.; Pandya, J.D.; Zhi, L.; Cass, W.A.; Sullivan, P.G.; Bueler, H. Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice. PLoS ONE 2011, 6, e16038
76. Gispert, S.; Ricciardi, F.; Kurz, A.; Azizov, M.; Hoepken, H.H.; Becker, D.; Voos, W.; Leuner, K.; Muller, W.E.; Kudin, A.P.; et al. Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS ONE 2009, 4, e5777
77. Stichel, C.C.; Zhu, X.R.; Bader, V.; Linnartz, B.; Schmidt, S.; Lubbert, H. Mono-and double-mutant mouse models of Parkinson’s disease display severe mitochondrial damage. Hum. Mol. Genet. 2007, 16, 2377-2393
78. Bonifati, V.; Oostra, B.A.; Heutink, P. Linking DJ-1 to neurodegeneration offers novel insights for understanding the pathogenesis of Parkinson’s disease. J. Mol. Med. (Berl.) 2004, 82, 163-174
79. Abou-Sleiman, P.M.; Healy, D.G.; Wood, N.W. Causes of Parkinson’s disease: Genetics of DJ-1. Cell Tissue Res. 2004, 318, 185-188
80. Zimprich, A.; Biskup, S.; Leitner, P.; Lichtner, P.; Farrer, M.; Lincoln, S.; Kachergus, J.; Hulihan, M.; Uitti, R.J.; Calne, D.B.; et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44, 601-607
81. Paisan-Ruiz, C.; Jain, S.; Evans, E.W.; Gilks, W.P.; Simon, J.; van der Brug, M.; de Munain, A.L.; Aparicio, S.; Gil, A.M.; Khan, N.; et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 2004, 44, 595-600
82. West, A.B.; Moore, D.J.; Choi, C.; Andrabi, S.A.; Li, X.; Dikeman, D.; Biskup, S.; Zhang, Z.; Lim, K.L.; Dawson, V.L.; et al. Parkinson’s disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 2007, 16, 223-232
83. Cookson, M.R. The role of leucinerich repeat kinase 2 (LRRK2) in Parkinson’s disease. Nat. Rev. Neurosci. 2010, 11, 791-797
84. West, A.B.; Moore, D.J.; Biskup, S.; Bugayenko, A.; Smith, W.W.; Ross, C.A.; Dawson, V.L.; Dawson, T.M. Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. USA 2005, 102, 16842-16847
85. Simon, H.H.; Saueressig, H.; Wurst, W.; Goulding, M.D.; O'Leary, D.D. Fate of midbrain dopaminergic neurons controlled by the engrailed genes. J. Neurosci. 2001, 21, 3126-3134
86. Yu-chin Su, X.Q.; Impairment of mitochondrial dynamics: A target for the treatment of neurological disorders? Future Med. 2013, 8, 333-346
87. Tanner, C.M.; Goldman, S.M. Epidemiology of Parkinson’s disease. Neurol. Clin. 1996, 14, 317-35
88. Caradoc-Davies, T.H.; Weatherall, M.; Dixon, G.S.; Caradoc-Davies, G.; Hantz, P. Is the prevalence of Parkinson’s disease in New Zealand really changing? Acta Neurol. Scand. 1992, 86, 40-44
89. Morgante, L.; Rocca, W.A.; di Rosa, A.E.; de Domenico, P.; Grigoletto, F.; Meneghini, F.; Reggio, A.; Savettieri, G.; Castiglione, M.G.; Patti, F.; et al. Prevalence of Parkinson’s disease and other types of parkinsonism: A door-to-door survey in three Sicilian municipalities. The Sicilian Neuro-Epidemiologic Study (SNES) Group. Neurology 1992, 42, 1901-1907
90. Mutch, W.J.; Dingwall-Fordyce, I.; Downie, A.W.; Paterson, J.G.; Roy, S.K. Parkinson’s disease in a Scottish city. Br. Med. J. (Clin. Res. Ed.) 1986, 292, 534-536
91. Polymeropoulos, M.H.; Higgins, J.J.; Golbe, L.I.; Johnson, W.G.; Ide, S.E.; di Iorio, G.; Sanges, G.; Stenroos, E.S.; Pho, L.T.; Schaffer, A.A.; et al. Mapping of a gene for Parkinson’s disease to chromosome 4q21-q23. Science 1996, 274, 1197-1199
92. Dekker, M.C.; Bonifati, V.; van Duijn, C.M. Parkinson’s disease: Piecing together a genetic jigsaw. Brain 2003, 126, 1722-1733
93. Langston, J.W. Epidemiology versus genetics in Parkinson’s disease: Progress in resolving an age-old debate. Ann. Neurol. 1998, 44 (Suppl. 1), S45-S52
94. Bowers, W.J.; Howard, D.F.; Federoff, H.J. Gene therapeutic strategies for neuroprotection: Implications for Parkinson’s disease. Exp. Neurol. 1997, 144, 58-68
95. Kitada, T.; Asakawa, S.; Hattori, N.; Matsumine, H.; Yamamura, Y.; Minoshima, S.; Yokochi, M.; Mizuno, Y.; Shimizu, N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392, 605-608
96. Lincoln, S.; Vaughan, J.; Wood, N.; Baker, M.; Adamson, J.; Gwinn-Hardy, K.; Lynch, T.; Hardy, J.; Farrer, M. Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson’s disease. Neuroreport 1999, 10, 427-429
97. Golbe, L.I.; Di Iorio, G.; Bonavita, V.; Miller, D.C.; Duvoisin, R.C. A large kindred with autosomal dominant Parkinson’s disease. Ann. Neurol. 1990, 27, 276-282
98. Kruger, R.; Kuhn, W.; Muller, T.; Woitalla, D.; Graeber, M.; Kosel, S.; Przuntek, H.; Epplen, J.T.; Schols, L.; Riess, O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat. Genet. 1998, 18, 106-108
99. Polymeropoulos, M.H.; Lavedan, C.; Leroy, E.; Ide, S.E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997, 276, 2045-2047
100. Pham, A.H.; Meng, S.; Chu, Q.N.; Chan, D.C. Loss of Mfn2 results in progressive, retrograde degeneration of dopaminergic neurons in the nigrostriatal circuit. Hum. Mol. Genet. 2012, 21, 4817-4826
101. Lee, S.; Sterky, F.H.; Mourier, A.; Terzioglu, M.; Cullheim, S.; Olson, L.; Larsson, N.G. Mitofusin 2 is necessary for striatal axonal projections of midbrain dopamine neurons. Hum. Mol. Genet. 2012, 21, 4827-35
102. Li, H.; Chen, Y.; Jones, A.F.; Sanger, R.H.; Collis, L.P.; Flannery, R.; McNay, E.C.; Yu, T.; Schwarzenbacher, R.; Bossy, B.; et al. Bcl-xL induces Drp1-dependent synapse formation in cultured hippocampal neurons. Proc. Natl. Acad. Sci. USA 2008, 105, 2169-2174
103. Ishihara, N.; Nomura, M.; Jofuku, A.; Kato, H.; Suzuki, S.O.; Masuda, K.; Otera, H.; Nakanishi, Y.; Nonaka, I.; Goto, Y.; et al. Mitochondrial fission factor Drp1 is essential for embryonic development and synapse formation in mice. Nat. Cell. Biol. 2009, 11, 958-966
104. Wakabayashi, J.; Zhang, Z.; Wakabayashi, N.; Tamura, Y.; Fukaya, M.; Kensler, T.W.; Iijima, M.; Sesaki, H. The dynamin-related GTPase Drp1 is required for embryonic and brain development in mice. J. Cell Biol. 2009, 186, 805-816
105. Berthet, A.; Margolis, E.B.; Zhang, J.; Hsieh, I.; Zhang, J.; Hnasko, T.S.; Ahmad, J.; Edwards, R.H.; Sesaki, H.; Huang, E.J.; et al. Loss of mitochondrial fission depletes axonal mitochondria in midbrain dopamine neurons. J. Neurosci. 2014, 34, 14304-14317
106. Zarranz, J.J.; Alegre, J.; Gomez-Esteban, J.C.; Lezcano, E.; Ros, R.; Ampuero, I.; Vidal, L.; Hoenicka, J.; Rodriguez, O.; Atares, B.; et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55, 164-173
107. Bonifati, V.; Rizzu, P.; Squitieri, F.; Krieger, E.; Vanacore, N.; van Swieten, J.C.; Brice, A.; van Duijn, C.M.; Oostra, B.; Meco, G.; et al. DJ-1(PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol. Sci. 2003, 24, 159-160
108. Iwatsubo, T.; Ito, G.; Takatori, S.; Hannno, Y.; Kuwahara, T. Pathogenesis of Parkinson’s disease: Implications from familial Parkinson’s disease. Rinsho Shinkeigaku 2005, 45, 899-901
109. Bialecka, M.; Hui, S.; Klodowska-Duda, G.; Opala, G.; Tan, E.K.; Drozdzik, M. Analysis of LRRK 2 G 2019 S and I 2020 T mutations in Parkinson’s disease. Neurosci. Lett. 2005, 390, 1-3
110. Smith, R.G. The aging process: Where are the drug opportunities? Curr. Opin. Chem. Biol. 2000, 4, 371-376
111. Le, W.; Conneely, O.M.; He, Y.; Jankovic, J.; Appel, S.H. Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J. Neurochem. 1999, 73, 2218-2221
112. Xiao, Q.; Castillo, S.O.; Nikodem, V.M. Distribution of messenger RNAs for the orphan nuclear receptors Nurr1 and Nur77 (NGFI-B) in adult rat brain using in situ hybridization. Neuroscience 1996, 75, 221-230
113. Rakovic, A.; Grunewald, A.; Seibler, P.; Ramirez, A.; Kock, N.; Orolicki, S.; Lohmann, K.; Klein, C. Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients. Hum. Mol. Genet. 2010, 19, 3124-3137
114. Rakovic, A.; Grunewald, A.; Kottwitz, J.; Bruggemann, N.; Pramstaller, P.P.; Lohmann, K.; Klein, C. Mutations in PINK1 and Parkin Impair Ubiquitination of Mitofusins in Human Fibroblasts. PLoS ONE 2011, 6, e16746
115. Jin, H.J.; Li, C.G. Tanshinone IIA and Cryptotanshinone Prevent Mitochondrial Dysfunction in Hypoxia-Induced H9c2 Cells: Association to Mitochondrial ROS, Intracellular Nitric Oxide, and Calcium Levels. Evid. Based Complement. Alternat. Med. 2013, 2013, 610694
116. Poole, A.C.; Thomas, R.E.; Andrews, L.A.; McBride, H.M.; Whitworth, A.J.; Pallanck, L.J. The PINK1/Parkin pathway regulates mitochondrial morphology. Proc. Natl. Acad. Sci. USA 2008, 105, 1638-1643
117. Yang, Y.; Ouyang, Y.; Yang, L.; Beal, M.F.; McQuibban, A.; Vogel, H.; Lu, B. Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proc. Natl. Acad. Sci. USA 2008, 105, 7070-7075
118. Yu, W.; Sun, Y.; Guo, S.; Lu, B. The PINK1/Parkin pathway regulates mitochondrial dynamics and function in mammalian hippocampal and dopaminergic neurons. Hum. Mol. Genet. 2011, 20, 3227-3240
119. Wang, X.; Petrie, T.G.; Liu, Y.; Liu, J.; Fujioka, H.; Zhu, X. Parkinson’s disease-associated DJ-1 mutations impair mitochondrial dynamics and cause mitochondrial dysfunction. J. Neurochem. 2012, 121, 830-839
120. Ryan, B.J.; Hoek, S.; Fon, E.A.; Wade-Martins, R. Mitochondrial dysfunction and mitophagy in Parkinson’s: From familial to sporadic disease. Trends Biochem. Sci. 2015, 40, 200-210
121. Niu, J.; Yu, M.; Wang, C.; Xu, Z. Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like protein. J. Neurochem. 2012, 122, 650-658
122. Wang, X.; Yan, M.H.; Fujioka, H.; Liu, J.; Wilson-Delfosse, A.; Chen, S.G.; Perry, G.; Casadesus, G.; Zhu, X. LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum. Mol. Genet. 2012, 21, 1931-1944
123. Su, Y.C.; Qi, X. Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation. Hum. Mol. Genet. 2013, 22, 4545-4561
124. Guo, X.; Disatnik, M.H.; Monbureau, M.; Shamloo, M.; Mochly-Rosen, D.; Qi, X. Inhibition of mitochondrial fragmentation diminishes Huntington’s disease-associated neurodegeneration. J. Clin. Investig. 2013, 123, 5371-5388
125. Qi, X.; Qvit, N.; Su, Y.C.; Mochly-Rosen, D. A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity. J. Cell Sci. 2013, 126, 789-802
126. Yamamoto, A.; Yue, Z. Autophagy and its normal and pathogenic states in the brain. Annu. Rev. Neurosci. 2014, 37, 55-78
127. Redmann, M.; Dodson, M.; Boyer-Guittaut, M.; Darley-Usmar, V.; Zhang, J. Mitophagy mechanisms and role in human diseases. Int. J. Biochem. Cell Biol. 2014, 53, 127-33
128. Fass, E.; Amar, N.; Elazar, Z. Identification of essential residues for the C-terminal cleavage of the mammalian LC3: A lesson from yeast Atg8. Autophagy 2007, 3, 48-50
129. Kabeya, Y.; Mizushima, N.; Ueno, T.; Yamamoto, A.; Kirisako, T.; Noda, T.; Kominami, E.; Ohsumi, Y.; Yoshimori, T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000, 19, 5720-5728
130. Kanki, T.; Wang, K.; Cao, Y.; Baba, M.; Klionsky, D.J. Atg32 is a mitochondrial protein that confers selectivity during mitophagy. Dev. Cell 2009, 17, 98-109
131. Okamoto, K.; Kondo-Okamoto, N.; Ohsumi, Y. Mitochondria-anchored receptor Atg32 mediates degradation of mitochondria via selective autophagy. Dev. Cell 2009, 17, 87-97
132. Liu, L.; Feng, D.; Chen, G.; Chen, M.; Zheng, Q.; Song, P.; Ma, Q.; Zhu, C.; Wang, R.; Qi, W.; et al. Mitochondrial outer-membrane protein FUNDC1 mediates hypoxia-induced mitophagy in mammalian cells. Nat. Cell Biol. 2012, 14, 177-185
133. Narendra, D.; Kane, L.A.; Hauser, D.N.; Fearnley, I.M.; Youle, R.J. p62/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both. Autophagy 2010, 6, 1090-1106
134. Shi, R.Y.; Zhu, S.H.; Li, V.; Gibson, S.B.; Xu, X.S.; Kong, J.M. BNIP3 interacting with LC3 triggers excessive mitophagy in delayed neuronal death in stroke. CNS Neurosci. Ther. 2014, 20, 1045-1055
135. Strappazzon, F.; Nazio, F.; Corrado, M.; Cianfanelli, V.; Romagnoli, A.; Fimia, G.M.; Campello, S.; Nardacci, R.; Piacentini, M.; Campanella, M.; et al. AMBRA1 is able to induce mitophagy via LC3 binding, regardless of PARKIN and p62/SQSTM1. Cell. Death Differ. 2015, 22, 419-432
136. Johansen, T.; Lamark, T. Selective autophagy mediated by autophagic adapter proteins. Autophagy 2011, 7, 279-296
137. Wu, F.; Xu, H.D.; Guan, J.J.; Hou, Y.S.; Gu, J.H.; Zhen, X.C., Qin, Z.H. Rotenone impairs autophagic flux and lysosomal functions in Parkinson’s disease. Neuroscience 2015, 284, 900-911
138. Arsikin, K.; Kravic-Stevovic, T.; Jovanovic, M.; Ristic, B.; Tovilovic, G.; Zogovic, N.; Bumbasirevic, V.; Trajkovic, V.; Harhaji-Trajkovic, L. Autophagy-dependent and-independent involvement of AMP-activated protein kinase in 6-hydroxydopamine toxicity to SH-SY5Y neuroblastoma cells. Biochim. Biophys. Acta 2012, 1822, 1826-1836
139. Youle, R.J.; Narendra, D.P. Mechanisms of mitophagy. Nat. Rev. Mol. Cell Biol. 2011, 12, 9-14
140. Narendra, D.P.; Youle, R.J. Targeting mitochondrial dysfunction: Role for PINK1 and Parkin in mitochondrial quality control. Antioxid. Redox Signal. 2011, 14, 1929-1938
141. Ashrafi, G.; Schlehe, J.S.; LaVoie, M.J.; Schwarz, T.L. Mitophagy of damaged mitochondria occurs locally in distal neuronal axons and requires PINK1 and Parkin. J. Cell Biol. 2014, 206, 655-670
142. Geisler, S.; Holmstrom, K.M.; Skujat, D.; Fiesel, F.C.; Rothfuss, O.C.; Kahle, P.J.; Springer, W. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat. Cell Biol. 2010, 12, 119-131
143. Rakovic, A.; Shurkewitsch, K.; Seibler, P.; Grunewald, A.; Zanon, A.; Hagenah, J.; Krainc, D.; Klein, C. Phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1)-dependent ubiquitination of endogenous Parkin attenuates mitophagy: Study in human primary fibroblasts and induced pluripotent stem cell-derived neurons. J. Biol. Chem. 2013, 288, 2223-2237
144. McCoy, M.K.; Cookson, M.R. DJ-1 regulation of mitochondrial function and autophagy through oxidative stress. Autophagy 2011, 7, 531-532
145. Thomas, K.J.; McCoy, M.K.; Blackinton, J.; Beilina, A.; van der Brug, M.; Sandebring, A.; Miller, D.; Maric, D.; Cedazo-Minguez, A.; Cookson, M.R. DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Hum. Mol. Genet. 2011, 20, 40-50
146. Irrcher, I.; Aleyasin, H.; Seifert, E.L.; Hewitt, S.J.; Chhabra, S.; Phillips, M.; Lutz, A.K.; Rousseaux, M.W.; Bevilacqua, L.; Jahani-Asl, A.; et al. Loss of the Parkinson’s disease-linked gene DJ-1 perturbs mitochondrial dynamics. Hum. Mol. Genet. 2010, 19, 3734-46
147. Tang, B.; Xiong, H.; Sun, P.; Zhang, Y.; Wang, D.; Hu, Z.; Zhu, Z.; Ma, H.; Pan, Q.; Xia, J.H.; et al. Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson’s disease. Hum. Mol. Genet. 2006, 15, 1816-1825
148. Xiong, H.; Wang, D.; Chen, L.; Choo, Y.S.; Ma, H.; Tang, C.; Xia, K.; Jiang, W.; Ronai, Z.; Zhuang, X.; et al. Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J. Clin. Investig. 2009, 119, 650-660
149. Plowey, E.D.; Cherra, S.J., 3rd; Liu, Y.J.; Chu, C.T. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J. Neurochem. 2008, 105, 1048-1056
150. Yakhine-Diop, S.M.; Bravo-San Pedro, J.M.; Gomez-Sanchez, R.; Pizarro-Estrella, E.; Rodriguez-Arribas, M.; Climent, V.; Aiastui, A.; Lopez de Munain, A.; Fuentes, J.M.; Gonzalez-Polo, R.A. G2019S LRRK2 mutant fibroblasts from Parkinson’s disease patients show increased sensitivity to neurotoxin 1-methyl-4-phenylpyridinium dependent of autophagy. Toxicology 2014, 324, 1-9
151. Sanchez-Danes, A.; Richaud-Patin, Y.; Carballo-Carbajal, I.; Jimenez-Delgado, S.; Caig, C.; Mora, S.; di Guglielmo, C.; Ezquerra, M.; Patel, B.; Giralt, A.; et al. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson’s disease. EMBO Mol. Med. 2012, 4, 380-395
152. Lachenmayer, M.L.; Yue, Z. Genetic animal models for evaluating the role of autophagy in etiopathogenesis of Parkinson disease. Autophagy 2012, 8, 1837-1838
153. Alegre-Abarrategui, J.; Christian, H.; Lufino, M.M.; Mutihac, R.; Venda, L.L.; Ansorge, O.; Wade-Martins, R. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum. Mol. Genet. 2009, 18, 4022-4034
154. Saez-Atienzar, S.; Bonet-Ponce, L.; Blesa, J.R.; Romero, F.J.; Murphy, M.P.; Jordan, J.; Galindo, M.F. The LRRK2 inhibitor GSK2578215A induces protective autophagy in SH-SY5Y cells: Involvement of Drp-1-mediated mitochondrial fission and mitochondrial-derived ROS signaling. Cell Death Dis. 2014, 5, e1368
155. Gomez-Suaga, P.; Luzon-Toro, B.; Churamani, D.; Zhang, L.; Bloor-Young, D.; Patel, S.; Woodman, P.G.; Churchill, G.C.; Hilfiker, S. Leucinerich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum. Mol. Genet. 2012, 21, 511-525
156. Bravo-San Pedro, J.M.; Niso-Santano, M.; Gomez-Sanchez, R.; Pizarro-Estrella, E.; Aiastui-Pujana, A.; Gorostidi, A.; Climent, V.; Lopez de Maturana, R.; Sanchez-Pernaute, R.; Lopez de Munain, A.; et al. The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway. Cell. Mol. Life Sci. 2013, 70, 121-136
157. Gomez-Suaga, P.; Hilfiker, S. LRRK2 as a modulator of lysosomal calcium homeostasis with downstream effects on autophagy. Autophagy 2012, 8, 692-693
158. Orenstein, S.J.; Kuo, S.H.; Tasset, I.; Arias, E.; Koga, H.; Fernandez-Carasa, I.; Cortes, E.; Honig, L.S.; Dauer, W.; Consiglio, A.; et al. Interplay of LRRK2 with chaperone-mediated autophagy. Nat. Neurosci. 2013, 16, 394-406
159. Su, Y.C.; Guo, X.; Qi, X. Threonine 56 phosphorylation of Bcl-2 is required for LRRK2 G2019S-induced mitochondrial depolarization and autophagy. Biochim. Biophys. Acta 2015, 1852, 12-21
160. Ramsay, R.R.; Salach, J.I.; Singer, T.P. Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. Biochem. Biophys. Res. Commun. 1986, 134, 743-748
161. Marey-Semper, I.; Gelman, M.; Levi-Strauss, M. The high sensitivity to rotenone of striatal dopamine uptake suggests the existence of a constitutive metabolic deficiency in dopaminergic neurons from the substantia nigra. Eur. J. Neurosci. 1993, 5, 1029-1034
162. Chinta, S.J.; Mallajosyula, J.K.; Rane, A.; Andersen, J.K. Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci. Lett. 2010, 486, 235-239
163. Devi, L.; Raghavendran, V.; Prabhu, B.M.; Avadhani, N.G.; Anandatheerthavarada, H.K. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 2008, 283, 9089-9100
164. Martin, L.J.; Pan, Y.; Price, A.C.; Sterling, W.; Copeland, N.G.; Jenkins, N.A.; Price, D.L.; Lee, M.K. Parkinson’s disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 2006, 26, 41-50
165. Zuo, L.; Motherwell, M.S. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson’s disease. Gene 2013, 532, 18-23
166. Nakamura, T.; Prikhodko, O.A.; Pirie, E.; Nagar, S.; Akhtar, M.W.; Oh, C.K.; McKercher, S.R.; Ambasudhan, R.; Okamoto, S.I.; Lipton, S.A. Aberrant protein S-nitrosylation contributes to the pathophysiology of neurodegenerative diseases. Neurobiol. Dis. 2015, doi:10.1016/j.nbd.2015.03.017
167. Van Muiswinkel, F.L.; Steinbusch, H.W.; Drukarch, B.; de Vente, J. Identification of NO-producing and-receptive cells in mesencephalic transplants in a rat model of Parkinson’s disease: A study using NADPH-d enzyme-and NOSc/cGMP immunocytochemistry. Ann. N. Y. Acad. Sci. 1994, 738, 289-304
168. Gu, Z.; Nakamura, T.; Lipton, S.A. Redox reactions induced by nitrosative stress mediate protein misfolding and mitochondrial dysfunction in neurodegenerative diseases. Mol. Neurobiol. 2010, 41, 55-72
169. Levecque, C.; Elbaz, A.; Clavel, J.; Richard, F.; Vidal, J.S.; Amouyel, P.; Tzourio, C.; Alperovitch, A.; Chartier-Harlin, M.C. Association between Parkinson’s disease and polymorphisms in the nNOS and iNOS genes in a community-based case-control study. Hum. Mol. Genet. 2003, 12, 79-86
170. Joniec, I.; Ciesielska, A.; Kurkowska-Jastrzebska, I.; Przybylkowski, A.; Czlonkowska, A.; Czlonkowski, A. Age-and sex-differences in the nitric oxide synthase expression and dopamine concentration in the murine model of Parkinson’s disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res. 2009, 1261, 7-19
171. Watanabe, Y.; Kato, H.; Araki, T. Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson’s disease. Metab. Brain Dis. 2008, 23, 51-69
172. Castagnoli, K.; Palmer, S.; Castagnoli, N., Jr. Neuroprotection by (R)-deprenyl and 7-nitroindazole in the MPTP C57BL/6 mouse model of neurotoxicity. Neurobiology (Bp) 1999, 7, 135-149
173. Dolezal, P.; Likic, V.; Tachezy, J.; Lithgow, T. Evolution of the molecular machines for protein import into mitochondria. Science 2006, 313, 314-318
174. De Marcos-Lousa, C.; Sideris, D.P.; Tokatlidis, K. Translocation of mitochondrial inner-membrane proteins: Conformation matters. Trends Biochem. Sci. 2006, 31, 259-267
175. Baker, M.J.; Frazier, A.E.; Gulbis, J.M.; Ryan, M.T. Mitochondrial protein-import machinery: Correlating structure with function. Trends Cell. Biol. 2007, 17, 456-464
176. Gottschalk, W.K.; Lutz, M.W.; He, Y.T.; Saunders, A.M.; Burns, D.K.; Roses, A.D.; Chiba-Falek, O. The Broad Impact of TOM40 on Neurodegenerative Diseases in Aging. J. Parkinsons Dis. Alzheimers Dis. 2014, 1, 12
177. Bender, A.; Desplats, P.; Spencer, B.; Rockenstein, E.; Adame, A.; Elstner, M.; Laub, C.; Mueller, S.; Koob, A.O.; Mante, M.; et al. TOM40 mediates mitochondrial dysfunction induced by alpha-synuclein accumulation in Parkinson’s disease. PLoS ONE 2013, 8, e62277
178. Okatsu, K.; Kimura, M.; Oka, T.; Tanaka, K.; Matsuda, N. Unconventional PINK1 localization to the outer membrane of depolarized mitochondria drives Parkin recruitment. J. Cell Sci. 2015, 128, 964-978
179. Kato, H.; Lu, Q.; Rapaport, D.; Kozjak-Pavlovic, V. Tom70 is essential for PINK1 import into mitochondria. PLoS ONE 2013, 8, e58435
180. Cooper, O.; Seo, H.; Andrabi, S.; Guardia-Laguarta, C.; Graziotto, J.; Sundberg, M.; McLean, J.R.; Carrillo-Reid, L.; Xie, Z.; Osborn, T.; et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson’s disease. Sci. Transl. Med. 2012, 4, 141ra90
181. Reinhardt, P.; Schmid, B.; Burbulla, L.F.; Schondorf, D.C.; Wagner, L.; Glatza, M.; Hoing, S.; Hargus, G.; Heck, S.A.; Dhingra, A.; et al. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell. Stem Cell. 2013, 12, 354-367
182. Toyoda, Y.; Erkut, C.; Pan-Montojo, F.; Boland, S.; Stewart, M.P.; Muller, D.J.; Wurst, W.; Hyman, A.A.; Kurzchalia, T.V. Products of the Parkinson’s disease-related glyoxalase DJ-1, D-lactate and glycolate, support mitochondrial membrane potential and neuronal survival. Biol. Open 2014, 3, 777-784
183. Daher, J.P.; Abdelmotilib, H.A.; Hu, X.; Volpicelli-Daley, L.A.; Moehle, M.S.; Fraser, K.B.; Needle, E.; Chen, Y.; Steyn, S.J.; Galatsis, P.; et al. LRRK2 Pharmacological Inhibition Abates alpha-Synuclein Induced Neurodegeneration. J. Biol. Chem. 2015, 290, 19433-19444
184. Li, T.; He, X.; Thomas, J.M.; Yang, D.; Zhong, S.; Xue, F.; Smith, W.W. A novel GTP-binding inhibitor, FX2149, attenuates LRRK2 toxicity in Parkinson’s disease models. PLoS ONE 2015, 10, e0122461
185. Chiu, C.C.; Yeh, T.H.; Lai, S.C.; Wu-Chou, Y.H.; Chen, C.H.; Mochly-Rosen, D.; Huang, Y.C.; Chen, Y.J.; Chen, C.L.; Chang, Y.M.; et al. Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and animal models of parkinsonism. Exp. Neurol. 2015, 263, 244-253
186. Richter, F.; Gao, F.; Medvedeva, V.; Lee, P.; Bove, N.; Fleming, S.M.; Michaud, M.; Lemesre, V.; Patassini, S.; de La Rosa, K.; et al. Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons. Neurobiol. Dis. 2014, 69, 263-275
187. Rappold, P.M.; Cui, M.; Grima, J.C.; Fan, R.Z.; de Mesy-Bentley, K.L.; Chen, L.; Zhuang, X.; Bowers, W.J.; Tieu, K. Drp1 inhibition attenuates neurotoxicity and dopamine release deficits in vivo. Nat. Commun. 2014, 5, 5244
188. Mena, N.P.; Garcia-Beltran, O.; Lourido, F.; Urrutia, P.J.; Mena, R.; Castro-Castillo, V.; Cassels, B.K.; Nunez, M.T. The novel mitochondrial iron chelator 5-((methylamino)methyl)-8-hydroxyquinoline protects against mitochondrial-induced oxidative damage and neuronal death. Biochem. Biophys. Res. Commun. 2015, 463, 787-792
189. Jiang, J.; Zuo, Y.; Gu, Z. Rapamycin protects the mitochondria against oxidative stress and apoptosis in a rat model of Parkinson’s disease. Int. J. Mol. Med. 2013, 31, 825-832
190. Xiong, N.; Xiong, J.; Khare, G.; Chen, C.; Huang, J.; Zhao, Y.; Zhang, Z.; Qiao, X.; Feng, Y.; Reesaul, H.; et al. Edaravone guards dopamine neurons in a rotenone model for Parkinson’s disease. PLoS ONE 2011, 6, e20677
191. Dabbeni-Sala, F.; di Santo, S.; Franceschini, D.; Skaper, S.D.; Giusti, P. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: A role for mitochondrial complex I activity. FASEB J. 2001, 15, 164-170
192. Zaitone, S.A.; Hammad, L.N.; Farag, N.E. Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice. Pharmacol. Rep. 2013, 65, 1213-1226
193. Karuppagounder, S.S.; Madathil, S.K.; Pandey, M.; Haobam, R.; Rajamma, U.; Mohanakumar, K.P. Quercetin upregulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinson’s disease in rats. Neuroscience 2013, 236, 136-148
194. Jayaraj, R.L.; Elangovan, N.; Dhanalakshmi, C.; Manivasagam, T.; Essa, M.M. CNB-001, a novel pyrazole derivative mitigates motor impairments associated with neurodegeneration via suppression of neuroinflammatory and apoptotic response in experimental Parkinson’s disease mice. Chem. Biol. Interact. 2014, 220, 149-157
195. Abdin, A.A.; Sarhan, N.I. Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of alpha-lipoic acid against rotenone-induced parkinsonism and L-dopa toxicity. Neurosci. Res. 2011, 71, 387-395
196. Kaur, H.; Chauhan, S.; Sandhir, R. Protective effect of lycopene on oxidative stress and cognitive decline in rotenone induced model of Parkinson’s disease. Neurochem. Res. 2011, 36, 1435-1443
197. Chen, C.H.; Budas, G.R.; Churchill, E.N.; Disatnik, M.H.; Hurley, T.D.; Mochly-Rosen, D. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 2008, 321, 1493-1145
198. Bordet, T.; Buisson, B.; Michaud, M.; Drouot, C.; Galea, P.; Delaage, P.; Akentieva, N.P.; Evers, A.S.; Covey, D.F.; Ostuni, M.A.; et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J. Pharmacol. Exp. Ther. 2007, 322, 709-720
199. Gouarne, C.; Tracz, J.; Paoli, M.G.; Deluca, V.; Seimandi, M.; Tardif, G.; Xilouri, M.; Stefanis, L.; Bordet, T.; Pruss, R.M. Protective role of olesoxime against wild-type alphasynuclein-induced toxicity in human neuronally differentiated SHSY-5Y cells. Br. J. Pharmacol. 2015, 172, 235-245
200. Fernandez-Moriano, C.; Gonzalez-Burgos, E.; Gomez-Serranillos, M.P. Mitochondria-Targeted Protective Compounds in Parkinson’s and Alzheimer’s Diseases. Oxid. Med. Cell. Longev. 2015, 2015, 408927
201. Valadas, J.S.; Vos, M.; Verstreken, P. Therapeutic strategies in Parkinson’s disease: What we have learned from animal models. Ann. N. Y. Acad. Sci. 2015, 1338, 16-37
202. Procaccio, V.; Bris, C.; de la Barca, J.M.C.; Oca, F.; Chevrollier, A.; Amati-Bonneau, P.; Bonneau, D.; Reynier, P. Perspectives of drug-based neuroprotection targeting mitochondria. Rev. Neurol. (Paris) 2014, 170, 390-400
203. Yadav, A.; Agarwal, S.; Tiwari, S.K.; Chaturvedi, R.K. Mitochondria: Prospective targets for neuroprotection in Parkinson’s disease. Curr. Pharm. Des. 2014, 20, 5558-5573